New Treatments for NASH
AASLD LiverLearning®. Tetri B. Nov 14, 2016; 154722
Topic: Steatohepatitis: Clinical
Disclosure(s): Dr. Tetri has provided consulting services to the following: Nimbus Therapeutics Bristol Myers Squibb Boehringer-Ingelheim Janssen Conatus Enanta Novartis Galmed Zafgen Receptos Pfizer Allergan MedImmune/AstraZeneca CoSynance Tobira
Dr. Brent Tetri
Dr. Brent Tetri

AASLD Members enjoy free LiverLearning® Premium Access. Registrants of The Liver Meeting® receive LiverLearning® Premium Access for one year from the first day of the meeting.

Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
1. Understand the pathogenesis of NASH based on the substrate overload lipotoxic liver injury (SOLLI) paradigm and how it predicts points of intervention.
2. Understand how lifestyle modification and drugs currently in clinical trials fit into this paradigm.
3. Understand that NASH is likely multifactorial in its underlying causes and these causes may differ in different patients.
There are currently no approved treatments for NASH. Lifestyle modification with a focus on healthy eating habits, weight loss when appropriate and regular exercise the mainstays of treatment but these are difficult for many patient to achieve and even more difficult to sustain. Bariatric surgery is effective for some patients but is not universally appropriate or accessible. Pharmacological treatment is currently being evaluated in clinical trials. Potential treatments can be broadly categorized into modulators of energy intake and disposal, modulators of adipose tissue inflammation and lipolysis, inhibitors of hepatic fatty acid synthesis (de novo lipogenesis), modulators of hepatocellular injury, inflammation, repair and cell death, and finally, modulators of fibrogenesis. Many of the treatments under evaluation focus on the downstream events, but effective modulation of energy intake (eg, modulators of satiety and eating behaviors) and modulators of energy efficiency and disposal may have the added benefit of addressing obesity and the other components of the metabolic syndrome. Effective treatment of NASH in the future will likely rely on a personalized approach based on our understanding of the underlying genetic, epigenetic and environmental contributors in each patient. For now, lifestyle modification plus an empiric approach to new therapies as they become available will likely be the general approach until we get smart enough to know who will respond to which therapies.
Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nature Reviews Disease Primers 2015;1:15080
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711-725.
Erikci Ertunc M, Hotamisligil GS. Lipid signaling and lipotoxicity in metabolic inflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res 2016; doi:10.1194/jlr.R066514
Hannah WN, Jr., Harrison SA. Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci 2016;61:1365-1374.
Hirsova P, Ibrahim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res 2016.
Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology 2016;doi: 10.1053/j.gastro.2016.02.066.
Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-788.
Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C. Exercise-based interventions for nonalcoholic fatty liver disease: A meta-analysis and meta-regression. Clin Gastroenterol Hepatol 2016;14:1398-1411.
Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov 2016.
Ratziu V. Novel pharmacotherapy options for NASH. Dig Dis Sci 2016;61:1398-1405.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-2273.
Code of conduct/disclaimer available in General Terms & Conditions